Leukoreduction on the agenda at US public health meeting in July:
This article was originally published in Clinica
Executive Summary
US public health officials have scheduled a public workshop on July 20 in Bethesda, Maryland, to discuss the latest developments in leukoreduction. Topics will include observed clinical adverse events and manufacturing failures, the FDA's current thinking about quality control tests and standards for the procedure, and new scientific developments in filtration, including developing a way to remove prions from blood. The workshop will be sponsored jointly by the FDA, the US National Heart Lung and Blood Institute and the Office of Public Health and Science in the US Department of Health and Human Services. For more information, or to register, contact Rhonda Dawson at the FDA's biologics centre, on tel: +1 301 827 3514; email: [email protected]